Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter  2021 and  raised  2021 guidance(3)  for  revenues  and Adjusted  diluted EPS(2)  driven by the  updated expectations  for  contributions  to  2021  performance  from  BNT162b2,  the  Pfizer-BioNTech  SE  (BioNTech)  COVID-19  vaccine,  as  well as the strong performance of the business excluding BNT162b2, partially offset by anticipated additional  R&D investments into vaccines to protect against COVID-19, as well as other mRNA-based development  programs  and COVID-19 antivirals.  

Additionally,  Pfizer  published this  morning  on its  website the  first-quarter  2021 earnings  presentation and  accompanying prepared remarks  from management.  

• First-Quarter  2021  Revenues  of  $14.6 Billion,  Reflecting  42%  Operational  Growth; Excluding  Revenues  for  BNT162b2  of $3.5  Billion, Revenues  Grew  8% Operationally  Including a  Negative 5% Impact  from Pricing  
• First-Quarter  2021 Reported Diluted  EPS(1)  of  $0.86, Adjusted Diluted  EPS(2)  of  $0.93  

• Raises Full-Year 2021  Guidance(3)  for Revenues to a Range of $70.5 to $72.5 Billion and Adjusted Diluted  EPS(2)  to a Range of $3.55 to $3.65, Primarily Reflecting Updates to Anticipated Contributions from  BNT162b2  Partially  Offset  by  Additional  R&D  Expenses  for  Vaccines  to  Protect  Against  COVID-19  as  Well  as  Other  mRNA-Based Development Programs  and COVID-19  Antivirals  

• Now  Anticipates  Revenues  of Approximately  $26  Billion  for BNT162b2,  Reflecting  1.6  Billion  Doses  Expected  to be Delivered in 2021 Under  Signed  Contracts  as  of Mid-April 2021  
• Raises Revenue Guidance Range Excluding BNT162b2 by $200 Million, Reflecting Continued Strong  Performance  of the Business  

• Enters  Into Contracts  to Supply  BNT162b2 to  Canada and  Israel  for  Periods  Beyond  2021; Currently  Negotiating  Similar  Potential  Contracts  with  Multiple Other Countries  
• Maintains  Quarterly  Dividend for  Second-Quarter 2021  at $0.39/Share;  Dividend  Will Not  Be Reduced  as  a  Result  of the Initiation of a Quarterly Dividend by  Viatris  Inc. (Viatris)

CWEB Analyst’s have initiated a Buy Rating for    Pfizer Inc. (NYSE: PFE) and potential upside of $99 in 2021. We believe that total revenue will grow faster than expenses in 2021. Revenue has doubled in some sectors of the company which is a very positive sign. We expect another jump in revenue in the second and third quarter of 2021. We also expect that Pfizer will start vaccine on young adults and maybe very young age kids and this will also increase their bottom line revenue.

https://cweb.com/stock/pfe